{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:05:15Z","timestamp":1789754715975,"version":"4.0.1"},"reference-count":20,"publisher":"BMJ","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015383","name":"Stichting voor Lever- en Maag-Darm Onderzoek","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100015383","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2026,8,26]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with immune tolerant (IT) chronic hepatitis B (CHB) have high viral loads, minimal inflammation and minimal fibrosis. Nevertheless, the benign nature of this phase and the need for antiviral therapy remain controversial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We explored the natural history of IT patients by assessing the risk of transition to immune active (IA) disease, fibrosis progression and hepatocellular carcinoma (HCC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>\n                      This international multicentre study from the RADICAL consortium includes mono-infected patients with CHB from sites around the world. The IT-phase was strictly defined as persistently (1) hepatitis B e-antigen (HBeAg)-positive, (2) alanine aminotransferase (ALT) \u226440\u2009U\/L, (3) HBV DNA &gt;7 log\n                      <jats:sub>10<\/jats:sub>\n                      IU\/mL and (4) F0-1 during the first year after baseline. We assessed the probabilities of transition to IA disease (ALT \u226550\u2009U\/L), the risk of significant fibrosis (\u2265F2) and HCC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 951 IT patients were included with a median age of 33, 40% were male with a median follow-up of 13 years. Median ALT and HBV DNA at baseline were 25.5\u2009U\/L and 8.4 log\n                      <jats:sub>10<\/jats:sub>\n                      IU\/mL.\n                    <\/jats:p>\n                    <jats:p>The probability of transitioning to IA disease was 51%, 67% and 72%\u2009before 5 years, 10 years and 15\u2009years. A high-normal ALT was associated with an increased risk of IA disease (subdistribution hazard ratio (sHR): 20\u201330\u2009U\/L: 1.744, p&lt;0.001, sHR: &gt;30U\/L: 3.130, p&lt;0.001). IT patients had a low risk of progression to significant fibrosis (15\u2009years: 6.3%), and HCC (15\u2009years: 1.1%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The majority of this large cohort of well-defined IT patients transition to IA disease within 5 years of follow-up, with the highest risk observed in those with a high-normal ALT, suggesting that these patients may benefit from either more frequent monitoring or pre-emptive therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gutjnl-2026-338784","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:20:40Z","timestamp":1789752040000},"page":"gutjnl-2026-338784","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["High rates of transition to immune active disease in a cohort of strictly defined immune tolerant patients with chronic hepatitis B: results from the RADICAL consortium"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0563-9037","authenticated-orcid":false,"given":"Lisa M","family":"van Velsen","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9158-1765","authenticated-orcid":false,"given":"Won-Mook","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Kilany","sequence":"additional","affiliation":[{"name":"Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norah A","family":"Terrault","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Southern California, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1819-2464","authenticated-orcid":false,"given":"Terry C F","family":"Yip","sequence":"additional","affiliation":[{"name":"Medical Data Analytics Centre, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong SAR, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3961-6123","authenticated-orcid":false,"given":"Karen","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Medicine and State Key Laboratory of Liver Research, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3534-6349","authenticated-orcid":false,"given":"Zillah","family":"Cargill","sequence":"additional","affiliation":[{"name":"Institute of Liver Studies, King\u2019s College Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8364-9152","authenticated-orcid":false,"given":"Gabriele","family":"Ricco","sequence":"additional","affiliation":[{"name":"Hepatology Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, Reference Center of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Battistella","sequence":"additional","affiliation":[{"name":"Hospital Clinic Barcelona, IDIBAPS and CIBEREHD, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2837-0188","authenticated-orcid":false,"given":"Marc G","family":"Ghany","sequence":"additional","affiliation":[{"name":"Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Vargas-Accarino","sequence":"additional","affiliation":[{"name":"Liver Unit, Hospital Universitari Vall d\u2019Hebron, Vall d\u2019Hebron Barcelona Hospital Campus and Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Narguet","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9patologie, AP-HP H\u00f4pital Beaujon, INSERM UMR 1149, CRI, Universit\u00e9 de Paris-Cit\u00e9, Clichy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zg\u00fcr M","family":"Koc","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A J","family":"Post","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Erasmus MC University Medical Center, Rotterdam, The Netherlands"},{"name":"Department of Biostatistics, Erasmus MC University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina E","family":"Hansen","sequence":"additional","affiliation":[{"name":"Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada"},{"name":"Department of Epidemiology, Erasmus MC University Medical Center, Rotterdam, The Netherlands"},{"name":"Department of Biostatistics, Erasmus MC University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Posthouwer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Microbiology, Maastricht University Medical Center, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0024-0595","authenticated-orcid":false,"given":"Tarik","family":"Asselah","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9patologie, AP-HP H\u00f4pital Beaujon, INSERM UMR 1149, CRI, Universit\u00e9 de Paris-Cit\u00e9, Clichy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Buti","sequence":"additional","affiliation":[{"name":"Liver Unit, Hospital Universitari Vall d\u2019Hebron, Vall d\u2019Hebron Barcelona Hospital Campus and Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4900-411X","authenticated-orcid":false,"given":"Sabela","family":"Lens","sequence":"additional","affiliation":[{"name":"Hospital Clinic Barcelona, IDIBAPS and CIBEREHD, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizia R","family":"Brunetto","sequence":"additional","affiliation":[{"name":"Hepatology Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, Reference Center of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa, Pisa, Italy"},{"name":"Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosh","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Institute of Liver Studies, King\u2019s College Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9012-313X","authenticated-orcid":false,"given":"Wai-Kay","family":"Seto","sequence":"additional","affiliation":[{"name":"Department of Medicine and State Key Laboratory of Liver Research, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man-Fung","family":"Yuen","sequence":"additional","affiliation":[{"name":"Department of Medicine and State Key Laboratory of Liver Research, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace L H","family":"Wong","sequence":"additional","affiliation":[{"name":"Medical Data Analytics Centre, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong SAR, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan J","family":"Feld","sequence":"additional","affiliation":[{"name":"Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8984-5103","authenticated-orcid":false,"given":"Yao-Chun","family":"Hsu","sequence":"additional","affiliation":[{"name":"Center for Liver Diseases, E-Da Hospital, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1544-577X","authenticated-orcid":false,"given":"Young-Suk","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9253-563X","authenticated-orcid":false,"given":"Milan J","family":"Sonneveld","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry L A","family":"Janssen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands"},{"name":"Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"2026091810202224000_gutjnl-2026-338784v1.1","unstructured":"World Health Organization . Guidelines for the Prevention, Diagnosis, Care and Treatment for People with Chronic Hepatitis B Infection. Geneva, 2024."},{"key":"2026091810202224000_gutjnl-2026-338784v1.2","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"83","year":"2025","journal-title":"J Hepatol"},{"key":"2026091810202224000_gutjnl-2026-338784v1.3","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800"},{"key":"2026091810202224000_gutjnl-2026-338784v1.4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.07.012"},{"key":"2026091810202224000_gutjnl-2026-338784v1.5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejim.2020.10.022","article-title":"Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B","volume":"84","author":"Lee","year":"2021","journal-title":"Eur J Intern Med"},{"key":"2026091810202224000_gutjnl-2026-338784v1.6","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-314904"},{"key":"2026091810202224000_gutjnl-2026-338784v1.7","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/apt.15725","article-title":"Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients","volume":"51","author":"Kim","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2026091810202224000_gutjnl-2026-338784v1.8","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/HEP.0000000000000845","article-title":"AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis","volume":"81","author":"Sterling","year":"2025","journal-title":"Hepatology"},{"key":"2026091810202224000_gutjnl-2026-338784v1.9","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2712"},{"key":"2026091810202224000_gutjnl-2026-338784v1.10","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v038.i07"},{"key":"2026091810202224000_gutjnl-2026-338784v1.11","doi-asserted-by":"publisher","DOI":"10.2307\/2670170"},{"key":"2026091810202224000_gutjnl-2026-338784v1.12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3350\/cmh.2020.0216","article-title":"Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B","volume":"27","author":"Jeon","year":"2021","journal-title":"Clin Mol Hepatol"},{"key":"2026091810202224000_gutjnl-2026-338784v1.13","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/hep.21724","article-title":"Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase","volume":"46","author":"Hui","year":"2007","journal-title":"Hepatology"},{"key":"2026091810202224000_gutjnl-2026-338784v1.14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cgh.2025.04.024","article-title":"Association of Metabolic Comorbidities With Fibrosis Severity and Fibrosis Regression in Patients With Chronic Hepatitis B","volume":"24","author":"van Velsen","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026091810202224000_gutjnl-2026-338784v1.15","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.cgh.2022.06.015","article-title":"Characteristics of Older Patients With Immunotolerant Chronic Hepatitis B Virus Infection","volume":"21","author":"Feld","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026091810202224000_gutjnl-2026-338784v1.16","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/apt.15741","article-title":"Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase","volume":"52","author":"Lee","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2026091810202224000_gutjnl-2026-338784v1.17","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23803"},{"key":"2026091810202224000_gutjnl-2026-338784v1.18","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.01.044"},{"key":"2026091810202224000_gutjnl-2026-338784v1.19","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.12.286"},{"key":"2026091810202224000_gutjnl-2026-338784v1.20","doi-asserted-by":"crossref","unstructured":"Tang S , Huang T , Tang R , et al . EASL 2025 indications revisited: phase-specific outcomes with and without nucleos(t)ide analogue therapy in chronic hepatitis B virus infection. Gut 2025.:gutjnl-2025-335449. doi:10.1136\/gutjnl-2025-335449","DOI":"10.1136\/gutjnl-2025-335449"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2026-338784","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:20:43Z","timestamp":1789752043000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2026-338784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":20,"alternative-id":["10.1136\/gutjnl-2026-338784"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2026-338784","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]}}}